Black Diamond narrows Q3 net loss as R&D costs drop

Black Diamond Therapeutics

06/11/2025 12:37

Overview

Black Diamond Q3 net loss narrows to $8.5 mln from $15.6 mln last year

Company's cash position at $135.5 mln, sufficient to fund operations into Q4 2027

R&D expenses decreased due to workforce efficiencies and outlicensing

Outlook

Company plans to release ORR and treatment duration data for silevertinib this quarter

Black Diamond expects FDA feedback on silevertinib path in H1 2026

Company has cash to fund operations into Q4 2027

Result Drivers

R&D EXPENSES - Decrease in R&D expenses attributed to workforce efficiencies and outlicensing of BDTX-4933

G&A EXPENSES - Reduction in G&A expenses due to restructuring efforts

SILEVERTINIB DEVELOPMENT - Focus on silevertinib development in NSCLC and GBM, with upcoming clinical data releases

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$8.50 mln
Q3 Basic EPS
-$0.15
Q3 Cash & Investments
$135.50 mln
Q3 Income From Operations
-$10.98 mln
Q3 Operating Expenses
$10.98 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $9.00, about 57% above its November 5 closing price of $3.87

Press Release: ID:nGNX67SFrZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)